Bliss GVS Pharma Q1 FY27 Unaudited Results: Revenue ₹221.58 Cr, Profit ₹38.61 Cr
Bliss GVS Pharma reported Q1 FY27 unaudited results. Standalone revenue was ₹221.58 crore and profit was ₹38.61 crore. Consolidated revenue was ₹256.99 crore and profit was ₹36.99 crore. The board also approved a postal ballot notice for the appointment of Mr. Santosh Parab as Director.
The announcement includes financial results and a director appointment, which are material events for the company, impacting investor decisions.
The company has announced its financial results and a key board appointment, indicating operational progress and corporate governance actions.
Bliss GVS Pharma Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company reported a standalone revenue from operations of ₹22,158.51 lakh (₹221.58 crore) and a net profit of ₹3,861.77 lakh (₹38.61 crore).
On a consolidated basis, the company's revenue from operations stood at ₹25,699.32 lakh (₹256.99 crore), with a net profit of ₹3,699.87 lakh (₹36.99 crore) for the same period.
The Board of Directors also approved the draft of the Postal Ballot Notice for the appointment of Mr. Santosh Parab as a Non-Executive Non-Independent Director. The Board meeting commenced at 4:22 p.m. and concluded at 6:15 p.m. on August 12, 2026. The financial results were reviewed by the Audit Committee and approved by the Board.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.